AstraZeneca and Bristol Myers in Talks for $400B Pharma Megamerger
BMY sits 54% above its 52-week low of $42.52.
Summary
AstraZeneca and Bristol Myers Squibb are in advanced merger talks that would create a $400 billion pharmaceutical giant, according to the Financial Times. Discussions have been ongoing for months, with a deal potentially imminent, though terms remain fluid and could still collapse. The combination would merge two massive oncology franchises, likely drawing antitrust scrutiny. For Bristol Myers, this follows a strong Q2 beat and raised guidance just days ago, adding a transformative M&A layer to an already positive narrative. The merger would likely involve a mix of cash and stock, with AstraZeneca as the acquirer given its larger market cap. This is a blockbuster development that would reshape the industry landscape.
At the time of this announcement, BMY was trading at $65.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $133.4B. The 52-week trading range was $42.52 to $65.66. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Benzinga.